Cingulate Inc., a Delaware-based pharmaceutical company, filed an amended registration statement with the Securities and Exchange Commission (SEC) on October 3, 2024. The amendment, identified as Amendment No. 1, was submitted to correct a typographical error in the auditor consent filed previously on September 26, 2024, under the registration number 333-282358. The amendment includes the facing page, explanatory note, Part II of the Registration Statement, signature page, exhibit index, and the corrected Exhibit 23.1. The prospectus remains unchanged and was omitted from this filing. The company, which falls under the primary standard industrial classification code number 2834, has its principal executive offices in Kansas City, KS. Cingulate Inc. has indicated that the sale of securities to the public will occur from time to time after the registration...Show More

Cingulate Inc., a Delaware-based pharmaceutical company, filed an amended registration statement with the Securities and Exchange Commission (SEC) on October 3, 2024. The amendment, identified as Amendment No. 1, was submitted to correct a typographical error in the auditor consent filed previously on September 26, 2024, under the registration number 333-282358. The amendment includes the facing page, explanatory note, Part II of the Registration Statement, signature page, exhibit index, and the corrected Exhibit 23.1. The prospectus remains unchanged and was omitted from this filing. The company, which falls under the primary standard industrial classification code number 2834, has its principal executive offices in Kansas City, KS. Cingulate Inc. has indicated that the sale of securities to the public will occur from time to time after the registration statement becomes effective, as determined by the selling stockholder. The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company under SEC regulations. The filing also details the company's indemnification policies for directors and officers, recent sales of unregistered securities, and various agreements and amendments related to the company's operations and management.